Oxford Biomedica PLC — Major Shareholding Notification 2016

Feb 25, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1942Q

Oxford Biomedica PLC

25 February 2016

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii				OXFORD BIOMEDICA PLC
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights					X
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: iii		VULPES LIFE SCIENCES FUND
4. Full name of shareholder(s) (if different from 3.):iv
5. Date of the transaction and date on which the threshold is crossed or reached: v		25 FEBRUARY 2016
6. Date on which issuer notified:		25 FEBRUARY 2016
7. Threshold(s) that is/are crossed or reached: vi, vii		<18%

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction						Resulting situation after the triggering transaction
Number of Shares			Number of Voting Rights			Number of shares		Number of voting rights			% of  voting rights x
Direct		Direct xi		Indirect xii	Direct			Indirect
GB0006648157	451,284,439			451,284,439			475,140,655		475,140,655			17.58%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument			Expiration date xiii		Exercise/ Conversion Period xiv					Number of voting rights that may be acquired if the instrument is exercised/ converted.				% of voting rights
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument		Exercise price		Expiration date xvii		Exercise/ Conversion period xviii			Number of voting rights instrument refers to				% of voting rights xix, xx
													Nominal			Delta
Total (A+B+C)
Number of voting rights								Percentage of voting rights
475,140,655								17.58%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:
14. Contact name:	Tim Watts, Chief Financial Officer Oxford BioMedica
15. Contact telephone number:	+44 (0) 1865 783 000

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLUVSSRNAAUUAR